newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences to Participate in Upcoming Conferences

  • Jade Biosciences, Inc. (NASDAQ: JBIO) announced its participation in four upcoming conferences starting in late February and March 2026.
  • The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 1:20 p.m. ET.
  • Jade will deliver a presentation & fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 10:30 a.m. ET.
  • A fireside chat is scheduled for the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 8:40 a.m. ET.
  • Members of the Jade management team will host one-on-one investor meetings during the Jefferies Biotech on the Beach Summit on March 10-11, 2026.
  • Live webcasts of all presentations will be available on the company website, with archived replays accessible for 90 days post-event.
  • Jade's lead candidate, JADE101, targets the cytokine APRIL and is currently in a Phase 1 clinical trial for immunoglobulin A nephropathy.
  • The pipeline includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed antibody program, both in preclinical development.
  • Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
  • The announcement includes standard forward-looking statement disclosures regarding risks such as safety signals, development delays, regulatory approval uncertainties, financial challenges, and reliance on SEC filings.